• Salvatore Patanè, Filippo Marte, Concetta Lentini, and Sergio Buonamonte.
• Int. J. Cardiol. 2010 Dec 3;145(3):e116-8.

AbstractRandomized clinical studies have demonstrated that tissue plasminogen activator thrombolytic therapy improves functional outcomes. Recently the time window for tissue plasminogen activator thrombolytic therapy has been extended from 3 to 4.5 h after ischemic stroke onset, which will allow more ischemic stroke patients to benefit from this treatment. Healthcare providers should also ascertain whether the ST-elevation myocardial infarction (STEMI) patient has also neurological contraindications to fibrinolytic therapy, including any history of intracranial hemorrhage, significant closed head or facial trauma within the past 3 months, uncontrolled hypertension, or ischemic stroke within the past 3 months (EXCEPT acute ischemic stroke within 3 h). History of prior ischemic stroke greater than 3 months is a relative contraindication. We present a case of tissue plasminogen activator thrombolytic therapy in a 68-year-old Italian man admitted to the Emergency Department with heart failure, ischemic stroke and ST-elevation myocardial infarction. Also this case focuses attention on regression of ischemic stroke symptoms in STEMI patient treated with tissue plasminogen activator thrombolytic therapy.Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

15 keywords...

hide…